{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:04:10Z","timestamp":1792605850093,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.phrs.2021.105445","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T11:55:00Z","timestamp":1611316500000},"page":"105445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Therapeutic potential of the FPR2\/ALX agonist AT-01-KG in the resolution of articular inflammation"],"prefix":"10.1016","volume":"165","author":[{"given":"Izabela","family":"Galv\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza M.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-5171","authenticated-orcid":false,"given":"Vivian L.S.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-3738","authenticated-orcid":false,"given":"Juliana P.","family":"Vago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Queiroz-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"de Gaetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4908-5474","authenticated-orcid":false,"given":"Eoin","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Gahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Guiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-3008","authenticated-orcid":false,"given":"Mauro M.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7203","key":"10.1016\/j.phrs.2021.105445_bib0005","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2021.105445_bib0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2010.02.029","article-title":"Nonresolving inflammation","volume":"140","author":"Nathan","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105445_bib0015","series-title":"Primary Osteoarthritis","author":"Aboulenain","year":"2020"},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0020","first-page":"33","article-title":"Gout or\u2019 pseudogout\u2019: how to differentiate crystal-induced arthropathies","volume":"50","author":"Joseph","year":"1995","journal-title":"Geriatrics"},{"issue":"2","key":"10.1016\/j.phrs.2021.105445_bib0025","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/ijms13021497","article-title":"Molecular diagnostic and pathogenesis of hereditary hemochromatosis","volume":"13","author":"Santos","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105445_bib0030","series-title":"Arthritis","author":"Senthelal","year":"2020"},{"issue":"2","key":"10.1016\/j.phrs.2021.105445_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020468","article-title":"Neutrophils: Beneficial and Harmful Cells in Septic Arthritis","volume":"19","author":"Boff","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2021.105445_bib0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2021.105445_bib0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1096\/fj.06-7227rev","article-title":"Resolution of inflammation: state of the art, definitions and terms","volume":"21","author":"Serhan","year":"2007","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.phrs.2021.105445_bib0050","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2019.01.007","article-title":"Mediators of the resolution of the inflammatory response","volume":"40","author":"Sugimoto","year":"2019","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105445_bib0055","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1152\/physrev.00026.2017","article-title":"Specialized proresolving mediators in innate and adaptive immune responses in airway diseases","volume":"98","author":"Krishnamoorthy","year":"2018","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2021.105445_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.180.1.253","article-title":"Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor","volume":"180","author":"Fiore","year":"1994","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.phrs.2021.105445_bib0065","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1124\/pr.58.3.4","article-title":"The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo","volume":"58","author":"Chiang","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2021.105445_bib0070","first-page":"181","article-title":"Lipoxins: nature\u2019s way to resolve inflammation","volume":"8","author":"Chandrasekharan","year":"2015","journal-title":"J. Inflamm. Res."},{"issue":"1","key":"10.1016\/j.phrs.2021.105445_bib0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.plefa.2013.04.005","article-title":"Lipoxin A(4) promotes more complete inflammation resolution in sepsis compared to stable lipoxin A(4) analog","volume":"89","author":"Wu","year":"2013","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.phrs.2021.105445_bib0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejmech.2018.10.049","article-title":"Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A4 mimetics (sLXms)","volume":"162","author":"de Gaetano","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2021.105445_bib0085","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2017101112","article-title":"Lipoxins regulate the early growth Response-1 network and reverse diabetic kidney disease","volume":"29","author":"Brennan","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105445_bib0090","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.2337\/db17-1317","article-title":"Lipoxins protect against inflammation in diabetes-associated atherosclerosis","volume":"67","author":"Brennan","year":"2018","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2021.105445_bib0095","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.4049\/jimmunol.0903526","article-title":"Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation","volume":"184","author":"Dufton","year":"2010","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105445_bib0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/art.33355","article-title":"NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout","volume":"64","author":"Amaral","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.phrs.2021.105445_bib0105","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/art.30448","article-title":"Resolution of neutrophilic inflammation by H2O2 in antigen-induced arthritis","volume":"63","author":"Lopes","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.phrs.2021.105445_bib0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/eji.201646551","article-title":"Annexin A1 promotes timely resolution of inflammation in murine gout","volume":"47","author":"Galvao","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105445_bib0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/eji.201545798","article-title":"Transmembrane TNF-alpha is sufficient for articular inflammation and hypernociception in a mouse model of gout","volume":"46","author":"Amaral","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105445_bib0120","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.4049\/jimmunol.1101195","article-title":"Experimental arthritis triggers periodontal disease in mice: involvement of TNF-alpha and the oral Microbiota","volume":"187","author":"Queiroz-Junior","year":"2011","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105445_bib0125","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3920\/BM2015.0015","article-title":"Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout","volume":"6","author":"Vieira","year":"2015","journal-title":"Benef. Microbes"},{"issue":"2","key":"10.1016\/j.phrs.2021.105445_bib0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1189\/jlb.0112008","article-title":"Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis","volume":"92","author":"Vago","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2021.105445_bib0135","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3389\/fphar.2018.01505","article-title":"The inhibition of Phosphoinositide-3 kinases induce resolution of inflammation in a gout model","volume":"9","author":"Galvao","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105445_bib0140","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.4049\/jimmunol.1203000","article-title":"Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2\/lipoxin A4 receptor","volume":"190","author":"Dalli","year":"2013","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105445_bib0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/pr.109.001578","article-title":"International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family","volume":"61","author":"Ye","year":"2009","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jlb.61.4.375","article-title":"Apoptosis in resolution of inflammation","volume":"61","author":"Savill","year":"1997","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105445_bib0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imr.12453","article-title":"Clearance of apoptotic neutrophils and resolution of inflammation","volume":"273","author":"Greenlee-Wacker","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2021.105445_bib0160","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3389\/fimmu.2017.01596","article-title":"Angiotensin-(1-7) promotes resolution of neutrophilic inflammation in a model of antigen-induced arthritis in mice","volume":"8","author":"Barroso","year":"2017","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105445_bib0165","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood.V94.12.4132","article-title":"Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions","volume":"94","author":"Filep","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1398-9995.1994.tb02654.x","article-title":"Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine","volume":"49","author":"Soyombo","year":"1994","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.phrs.2021.105445_bib0175","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120932","article-title":"I. Blood Institute\u2019s Severe Asthma Research Program, ALX receptor ligands define a biochemical endotype for severe asthma","volume":"3","author":"Ricklefs","year":"2018","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.phrs.2021.105445_bib0180","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1084\/jem.189.12.1923","article-title":"Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis","volume":"189","author":"Hachicha","year":"1999","journal-title":"J. Exp. Med."},{"issue":"24","key":"10.1016\/j.phrs.2021.105445_bib0185","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1021\/jm060270d","article-title":"Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities","volume":"50","author":"O\u2019Sullivan","year":"2007","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0190","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1476-5381.2010.00950.x","article-title":"Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects","volume":"161","author":"Conte","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105445_bib0195","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2021.105445_bib0200","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/rheumatology\/keh640","article-title":"Mechanisms of inflammation in gout","volume":"44","author":"Dalbeth","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.phrs.2021.105445_bib0205","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9259646","article-title":"Biologics for targeting inflammatory cytokines, clinical uses, and limitations","volume":"2016","author":"Rider","year":"2016","journal-title":"Int. J. Cell Biol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00011-007-7141-z","article-title":"BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm. Res."},{"issue":"11","key":"10.1016\/j.phrs.2021.105445_bib0215","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/nm786","article-title":"Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor","volume":"8","author":"Perretti","year":"2002","journal-title":"Nat. Med."},{"issue":"29","key":"10.1016\/j.phrs.2021.105445_bib0220","doi-asserted-by":"crossref","first-page":"24690","DOI":"10.1074\/jbc.M112.377101","article-title":"Annexin A1 interaction with the FPR2\/ALX receptor: identification of distinct domains and downstream associated signaling","volume":"287","author":"Bena","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0225","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.phrs.2021.105445_bib0230","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1111\/bph.15212","article-title":"Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology","volume":"177","author":"Perretti","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105445_bib0235","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/jm501051x","article-title":"FPR2\/ALXR agonists and the resolution of inflammation","volume":"58","author":"Corminboeuf","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2021.105445_bib0240","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmet.2015.05.003","article-title":"Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease","volume":"22","author":"Borgeson","year":"2015","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.phrs.2021.105445_bib0245","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/jcb.22351","article-title":"Neutrophil apoptosis: a target for enhancing the resolution of inflammation","volume":"108","author":"Filep","year":"2009","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0250","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.200810-1601OC","article-title":"15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury","volume":"180","author":"El Kebir","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0255","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.164.4.1663","article-title":"Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages","volume":"164","author":"Godson","year":"2000","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.phrs.2021.105445_bib0260","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1097\/01.ASN.0000032417.73640.72","article-title":"Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo","volume":"13","author":"Mitchell","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105445_bib0265","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.4049\/jimmunol.176.3.1878","article-title":"Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes","volume":"176","author":"Reville","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2021.105445_bib0270","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1039\/c0md00136h","article-title":"Recent advances in the chemistry and biology of stable synthetic Lipoxin analogues","author":"Duffy","year":"2010","journal-title":"Med.Chem.Comm."},{"issue":"4","key":"10.1016\/j.phrs.2021.105445_bib0275","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cmdc.200900533","article-title":"Synthesis and Biological Evaluation of Pyridine\u2010Containing Lipoxin A4 Analogues","volume":"5","author":"Duffy","year":"2010","journal-title":"ChemMedChem"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:21:39Z","timestamp":1760912499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":55,"alternative-id":["S1043661821000281"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105445","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of the FPR2\/ALX agonist AT-01-KG in the resolution of articular inflammation","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105445"}}